Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

TIVC vs STIM vs ELMD vs NVCR vs HOLX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TIVC
Tivic Health Systems, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$3M
5Y Perf.-100.0%
STIM
Neuronetics, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$115M
5Y Perf.-49.9%
ELMD
Electromed, Inc.

Medical - Devices

HealthcareAMEX • US
Market Cap$223M
5Y Perf.+113.9%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.04B
5Y Perf.-83.8%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+1.2%

TIVC vs STIM vs ELMD vs NVCR vs HOLX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TIVC logoTIVC
STIM logoSTIM
ELMD logoELMD
NVCR logoNVCR
HOLX logoHOLX
IndustryMedical - DevicesMedical - Diagnostics & ResearchMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$3M$115M$223M$2.04B$16.97B
Revenue (TTM)$482K$152M$69M$674M$4.13B
Net Income (TTM)$-8M$-37M$9M$-173M$544M
Gross Margin-58.1%48.0%78.2%75.2%52.8%
Operating Margin-15.5%-19.4%16.7%-27.2%17.5%
Forward P/E24.5x17.2x
Total Debt$0.00$90M$198K$290M$2.63B
Cash & Equiv.$2M$34M$15M$103M$1.96B

TIVC vs STIM vs ELMD vs NVCR vs HOLXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TIVC
STIM
ELMD
NVCR
HOLX
StockNov 21May 26Return
Tivic Health System… (TIVC)1000.0-100.0%
Neuronetics, Inc. (STIM)10050.1-49.9%
Electromed, Inc. (ELMD)100213.9+113.9%
NovoCure Limited (NVCR)10016.2-83.8%
Hologic, Inc. (HOLX)100101.2+1.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: TIVC vs STIM vs ELMD vs NVCR vs HOLX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HOLX leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Neuronetics, Inc. is the stronger pick specifically for growth and revenue expansion. ELMD also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
TIVC
Tivic Health Systems, Inc.
The Healthcare Pick

TIVC lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
STIM
Neuronetics, Inc.
The Growth Play

STIM is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 99.2%, EPS growth 57.2%, 3Y rev CAGR 31.8%
  • 99.2% revenue growth vs TIVC's -33.7%
Best for: growth exposure
ELMD
Electromed, Inc.
The Long-Run Compounder

ELMD ranks third and is worth considering specifically for long-term compounding and sleep-well-at-night.

  • 484.2% 10Y total return vs HOLX's 124.3%
  • Lower volatility, beta 1.01, Low D/E 0.5%, current ratio 4.31x
  • 16.4% ROA vs TIVC's -173.3%, ROIC 25.6% vs -7.8%
Best for: long-term compounding and sleep-well-at-night
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
HOLX
Hologic, Inc.
The Income Pick

HOLX carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • beta 0.45
  • Beta 0.45, current ratio 3.75x
  • Better valuation composite
  • 13.2% margin vs TIVC's -15.6%
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthSTIM logoSTIM99.2% revenue growth vs TIVC's -33.7%
ValueHOLX logoHOLXBetter valuation composite
Quality / MarginsHOLX logoHOLX13.2% margin vs TIVC's -15.6%
Stability / SafetyHOLX logoHOLXBeta 0.45 vs TIVC's 2.20
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)HOLX logoHOLX+35.3% vs TIVC's -74.9%
Efficiency (ROA)ELMD logoELMD16.4% ROA vs TIVC's -173.3%, ROIC 25.6% vs -7.8%

TIVC vs STIM vs ELMD vs NVCR vs HOLX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TIVCTivic Health Systems, Inc.
FY 2024
Shipping and Handling
100.0%$1,000
STIMNeuronetics, Inc.
FY 2025
Clinical Services Segment
58.3%$87M
Medical Device Segment
41.7%$62M
ELMDElectromed, Inc.
FY 2024
Home Care
50.4%$841,000
Other
49.6%$826,000
NVCRNovoCure Limited

Segment breakdown not available.

HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M

TIVC vs STIM vs ELMD vs NVCR vs HOLX — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHOLXLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

HOLX leads this category, winning 3 of 6 comparable metrics.

HOLX is the larger business by revenue, generating $4.1B annually — 8561.0x TIVC's $482,000. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to TIVC's -15.6%. On growth, ELMD holds the edge at +16.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTIVC logoTIVCTivic Health Syst…STIM logoSTIMNeuronetics, Inc.ELMD logoELMDElectromed, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
RevenueTrailing 12 months$482,000$152M$69M$674M$4.1B
EBITDAEarnings before interest/tax-$7M-$27M$12M-$165M$974M
Net IncomeAfter-tax profit-$8M-$37M$9M-$173M$544M
Free Cash FlowCash after capex-$6M-$4M$9M-$48M$1000M
Gross MarginGross profit ÷ Revenue-58.1%+48.0%+78.2%+75.2%+52.8%
Operating MarginEBIT ÷ Revenue-15.5%-19.4%+16.7%-27.2%+17.5%
Net MarginNet income ÷ Revenue-15.6%-24.5%+13.1%-25.7%+13.2%
FCF MarginFCF ÷ Revenue-12.7%-2.6%+13.4%-7.1%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year+15.9%+7.8%+16.3%+12.3%+2.5%
EPS Growth (YoY)Latest quarter vs prior year+49.9%+23.8%+45.5%-100.0%-9.2%
HOLX leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

HOLX leads this category, winning 4 of 6 comparable metrics.

At 30.5x trailing earnings, HOLX trades at a 3% valuation discount to ELMD's 31.3x P/E. On an enterprise value basis, HOLX's 17.4x EV/EBITDA is more attractive than ELMD's 19.2x.

MetricTIVC logoTIVCTivic Health Syst…STIM logoSTIMNeuronetics, Inc.ELMD logoELMDElectromed, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
Market CapShares × price$3M$115M$223M$2.0B$17.0B
Enterprise ValueMkt cap + debt − cash$624,809$171M$208M$2.2B$17.6B
Trailing P/EPrice ÷ TTM EPS-0.05x-2.81x31.31x-14.66x30.53x
Forward P/EPrice ÷ next-FY EPS est.24.48x17.21x
PEG RatioP/E ÷ EPS growth rate2.44x
EV / EBITDAEnterprise value multiple19.19x17.39x
Price / SalesMarket cap ÷ Revenue3.37x0.77x3.48x3.11x4.14x
Price / BookPrice ÷ Book value/share117.90x4.16x5.43x5.86x3.43x
Price / FCFMarket cap ÷ FCF20.11x18.44x
HOLX leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

ELMD leads this category, winning 7 of 9 comparable metrics.

ELMD delivers a 19.8% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-2 for TIVC. ELMD carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to STIM's 3.44x. On the Piotroski fundamental quality scale (0–9), ELMD scores 7/9 vs TIVC's 3/9, reflecting strong financial health.

MetricTIVC logoTIVCTivic Health Syst…STIM logoSTIMNeuronetics, Inc.ELMD logoELMDElectromed, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
ROE (TTM)Return on equity-2.0%-139.8%+19.8%-50.8%+11.0%
ROA (TTM)Return on assets-173.3%-27.1%+16.4%-16.5%+6.1%
ROICReturn on invested capital-7.8%-26.6%+25.6%-16.4%+9.4%
ROCEReturn on capital employed-180.0%-28.5%+22.0%-28.9%+8.8%
Piotroski ScoreFundamental quality 0–934757
Debt / EquityFinancial leverage3.44x0.00x0.85x0.52x
Net DebtTotal debt minus cash-$2M$56M-$15M$187M$667M
Cash & Equiv.Liquid assets$2M$34M$15M$103M$2.0B
Total DebtShort + long-term debt$0$90M$198,000$290M$2.6B
Interest CoverageEBIT ÷ Interest expense-2.43x-96.80x8.00x
ELMD leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ELMD leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ELMD five years ago would be worth $26,849 today (with dividends reinvested), compared to $1 for TIVC. Over the past 12 months, HOLX leads with a +35.3% total return vs TIVC's -74.9%. The 3-year compound annual growth rate (CAGR) favors ELMD at 34.9% vs TIVC's -83.2% — a key indicator of consistent wealth creation.

MetricTIVC logoTIVCTivic Health Syst…STIM logoSTIMNeuronetics, Inc.ELMD logoELMDElectromed, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
YTD ReturnYear-to-date-26.8%+14.9%-1.7%+36.4%+1.9%
1-Year ReturnPast 12 months-74.9%-64.4%+21.1%+2.6%+35.3%
3-Year ReturnCumulative with dividends-99.5%-24.8%+145.3%-74.2%-8.5%
5-Year ReturnCumulative with dividends-100.0%-87.3%+168.5%-90.2%+16.8%
10-Year ReturnCumulative with dividends-100.0%-94.0%+484.2%+38.5%+124.3%
CAGR (3Y)Annualised 3-year return-83.2%-9.1%+34.9%-36.4%-2.9%
ELMD leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

HOLX leads this category, winning 2 of 2 comparable metrics.

HOLX is the less volatile stock with a 0.45 beta — it tends to amplify market swings less than TIVC's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs TIVC's 18.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTIVC logoTIVCTivic Health Syst…STIM logoSTIMNeuronetics, Inc.ELMD logoELMDElectromed, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
Beta (5Y)Sensitivity to S&P 5002.20x1.77x1.01x2.15x0.45x
52-Week HighHighest price in past year$5.60$4.85$30.73$20.06$76.04
52-Week LowLowest price in past year$0.74$0.80$17.73$9.82$53.62
% of 52W HighCurrent price vs 52-week peak+18.6%+34.1%+87.6%+89.2%+100.0%
RSI (14)Momentum oscillator 0–10048.656.363.170.969.1
Avg Volume (50D)Average daily shares traded344K2.0M41K1.4M10.3M
HOLX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: STIM as "Buy", ELMD as "Buy", NVCR as "Buy", HOLX as "Hold". Consensus price targets imply 383.4% upside for STIM (target: $8) vs 3.9% for HOLX (target: $79).

MetricTIVC logoTIVCTivic Health Syst…STIM logoSTIMNeuronetics, Inc.ELMD logoELMDElectromed, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHold
Price TargetConsensus 12-month target$8.00$38.00$33.50$79.00
# AnalystsCovering analysts741542
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+4.5%0.0%+4.4%
Insufficient data to determine a leader in this category.
Key Takeaway

HOLX leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). ELMD leads in 2 (Profitability & Efficiency, Total Returns).

Best OverallHologic, Inc. (HOLX)Leads 3 of 6 categories
Loading custom metrics...

TIVC vs STIM vs ELMD vs NVCR vs HOLX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TIVC or STIM or ELMD or NVCR or HOLX a better buy right now?

For growth investors, Neuronetics, Inc.

(STIM) is the stronger pick with 99. 2% revenue growth year-over-year, versus -33. 7% for Tivic Health Systems, Inc. (TIVC). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Neuronetics, Inc. (STIM) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TIVC or STIM or ELMD or NVCR or HOLX?

On trailing P/E, Hologic, Inc.

(HOLX) is the cheapest at 30. 5x versus Electromed, Inc. at 31. 3x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x.

03

Which is the better long-term investment — TIVC or STIM or ELMD or NVCR or HOLX?

Over the past 5 years, Electromed, Inc.

(ELMD) delivered a total return of +168. 5%, compared to -100. 0% for Tivic Health Systems, Inc. (TIVC). Over 10 years, the gap is even starker: ELMD returned +484. 2% versus TIVC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TIVC or STIM or ELMD or NVCR or HOLX?

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus Tivic Health Systems, Inc. 's 2. 20β — meaning TIVC is approximately 385% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 3% for Neuronetics, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — TIVC or STIM or ELMD or NVCR or HOLX?

By revenue growth (latest reported year), Neuronetics, Inc.

(STIM) is pulling ahead at 99. 2% versus -33. 7% for Tivic Health Systems, Inc. (TIVC). On earnings-per-share growth, the picture is similar: Tivic Health Systems, Inc. grew EPS 88. 9% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, STIM leads at 31. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TIVC or STIM or ELMD or NVCR or HOLX?

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -725. 0% for Tivic Health Systems, Inc. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -725. 8% for TIVC. At the gross margin level — before operating expenses — ELMD leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TIVC or STIM or ELMD or NVCR or HOLX more undervalued right now?

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 24. 5x for Electromed, Inc. — 7. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for STIM: 383. 4% to $8. 00.

08

Which pays a better dividend — TIVC or STIM or ELMD or NVCR or HOLX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is TIVC or STIM or ELMD or NVCR or HOLX better for a retirement portfolio?

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), +124. 3% 10Y return). Tivic Health Systems, Inc. (TIVC) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, TIVC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TIVC and STIM and ELMD and NVCR and HOLX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TIVC is a small-cap quality compounder stock; STIM is a small-cap high-growth stock; ELMD is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

TIVC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
Run This Screen
Stocks Like

STIM

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 28%
Run This Screen
Stocks Like

ELMD

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 8%
  • Net Margin > 7%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform TIVC and STIM and ELMD and NVCR and HOLX on the metrics below

Revenue Growth>
%
(TIVC: 15.9% · STIM: 7.8%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.